Selected research
Industry Research
Central Nervous System (CNS) Drug Industry Research Report 2026
Market perspective
The global Central Nervous System (CNS) Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Central Nervous System (CNS) Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Central Nervous System (CNS) Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Central Nervous System (CNS) Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Central Nervous System (CNS) Drug include Tekeda, Teva, Shanghai Fosun, Johnson & Johnson, Novartis AG, Roche, Eli Lilly, Jiangsu Nhwa Pharmaceutical Co., Ltd. and Pfizer Inc, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Central Nervous System (CNS) Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Central Nervous System (CNS) Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Central Nervous System (CNS) Drug Market by Company
Tekeda
Teva
Shanghai Fosun
Johnson & Johnson
Novartis AG
Roche
Eli Lilly
Jiangsu Nhwa Pharmaceutical Co., Ltd.
Pfizer Inc
GSK
UCB
Otsuka Pharmaceutical Co., Ltd
Boehringer Ingelheim
Biogen Inc
Central Nervous System (CNS) Drug Segment by Type
Prescription Drugs
OTC
Central Nervous System (CNS) Drug Segment by Application
Epilepsy Drugs
MS Therapeutics
Antipsychotic Drugs
Depression Drugs
Others
Central Nervous System (CNS) Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Central Nervous System (CNS) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Central Nervous System (CNS) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Central Nervous System (CNS) Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Central Nervous System (CNS) Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Prescription Drugs
- OTC
Applications
- Epilepsy Drugs
- MS Therapeutics
- Antipsychotic Drugs
- Depression Drugs
- Others
Companies covered
- Tekeda
- Teva
- Shanghai Fosun
- Johnson & Johnson
- Novartis AG
- Roche
- Eli Lilly
- Jiangsu Nhwa Pharmaceutical Co., Ltd.
- Pfizer Inc
- GSK
- UCB
- Otsuka Pharmaceutical Co., Ltd
- Boehringer Ingelheim
- Biogen Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Central Nervous System (CNS) Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Prescription Drugs
- 2.2.3 OTC
- 2.3 Central Nervous System (CNS) Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Epilepsy Drugs
- 2.3.3 MS Therapeutics
- 2.3.4 Antipsychotic Drugs
- 2.3.5 Depression Drugs
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 Central Nervous System (CNS) Drug Breakdown Data by Type
- 3.1 Global Central Nervous System (CNS) Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Central Nervous System (CNS) Drug Forecasted Market Size by Type (2027-2032)
4 Central Nervous System (CNS) Drug Breakdown Data by Application
- 4.1 Global Central Nervous System (CNS) Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Central Nervous System (CNS) Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Central Nervous System (CNS) Drug Market Perspective (2021-2032)
- 5.2 Global Central Nervous System (CNS) Drug Growth Trends by Region
- 5.2.1 Global Central Nervous System (CNS) Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Central Nervous System (CNS) Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Central Nervous System (CNS) Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Central Nervous System (CNS) Drug Market Dynamics
- 5.3.1 Central Nervous System (CNS) Drug Industry Trends
- 5.3.2 Central Nervous System (CNS) Drug Market Drivers
- 5.3.3 Central Nervous System (CNS) Drug Market Challenges
- 5.3.4 Central Nervous System (CNS) Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Central Nervous System (CNS) Drug Players by Revenue
- 6.1.1 Global Top Central Nervous System (CNS) Drug Players by Revenue (2021-2026)
- 6.1.2 Global Central Nervous System (CNS) Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Central Nervous System (CNS) Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Central Nervous System (CNS) Drug Head Office and Area Served
- 6.4 Global Central Nervous System (CNS) Drug Players, Product Type & Application
- 6.5 Global Central Nervous System (CNS) Drug Manufacturers Established Date
- 6.6 Global Central Nervous System (CNS) Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Central Nervous System (CNS) Drug Market Size (2021-2032)
- 7.2 North America Central Nervous System (CNS) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Central Nervous System (CNS) Drug Market Size by Country (2021-2026)
- 7.4 North America Central Nervous System (CNS) Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Central Nervous System (CNS) Drug Market Size (2021-2032)
- 8.2 Europe Central Nervous System (CNS) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Central Nervous System (CNS) Drug Market Size by Country (2021-2026)
- 8.4 Europe Central Nervous System (CNS) Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Central Nervous System (CNS) Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Central Nervous System (CNS) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Central Nervous System (CNS) Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Central Nervous System (CNS) Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Central Nervous System (CNS) Drug Market Size (2021-2032)
- 10.2 South America Central Nervous System (CNS) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Central Nervous System (CNS) Drug Market Size by Country (2021-2026)
- 10.4 South America Central Nervous System (CNS) Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Central Nervous System (CNS) Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Central Nervous System (CNS) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Central Nervous System (CNS) Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Central Nervous System (CNS) Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Tekeda
- 12.1.1 Tekeda Company Information
- 12.1.2 Tekeda Business Overview
- 12.1.3 Tekeda Revenue in Central Nervous System (CNS) Drug Business (2021-2026)
- 12.1.4 Tekeda Central Nervous System (CNS) Drug Product Portfolio
- 12.1.5 Tekeda Recent Developments
- 12.2 Teva
- 12.2.1 Teva Company Information
- 12.2.2 Teva Business Overview
- 12.2.3 Teva Revenue in Central Nervous System (CNS) Drug Business (2021-2026)
- 12.2.4 Teva Central Nervous System (CNS) Drug Product Portfolio
- 12.2.5 Teva Recent Developments
- 12.3 Shanghai Fosun
- 12.3.1 Shanghai Fosun Company Information
- 12.3.2 Shanghai Fosun Business Overview
- 12.3.3 Shanghai Fosun Revenue in Central Nervous System (CNS) Drug Business (2021-2026)
- 12.3.4 Shanghai Fosun Central Nervous System (CNS) Drug Product Portfolio
- 12.3.5 Shanghai Fosun Recent Developments
- 12.4 Johnson & Johnson
- 12.4.1 Johnson & Johnson Company Information
- 12.4.2 Johnson & Johnson Business Overview
- 12.4.3 Johnson & Johnson Revenue in Central Nervous System (CNS) Drug Business (2021-2026)
- 12.4.4 Johnson & Johnson Central Nervous System (CNS) Drug Product Portfolio
- 12.4.5 Johnson & Johnson Recent Developments
- 12.5 Novartis AG
- 12.5.1 Novartis AG Company Information
- 12.5.2 Novartis AG Business Overview
- 12.5.3 Novartis AG Revenue in Central Nervous System (CNS) Drug Business (2021-2026)
- 12.5.4 Novartis AG Central Nervous System (CNS) Drug Product Portfolio
- 12.5.5 Novartis AG Recent Developments
- 12.6 Roche
- 12.6.1 Roche Company Information
- 12.6.2 Roche Business Overview
- 12.6.3 Roche Revenue in Central Nervous System (CNS) Drug Business (2021-2026)
- 12.6.4 Roche Central Nervous System (CNS) Drug Product Portfolio
- 12.6.5 Roche Recent Developments
- 12.7 Eli Lilly
- 12.7.1 Eli Lilly Company Information
- 12.7.2 Eli Lilly Business Overview
- 12.7.3 Eli Lilly Revenue in Central Nervous System (CNS) Drug Business (2021-2026)
- 12.7.4 Eli Lilly Central Nervous System (CNS) Drug Product Portfolio
- 12.7.5 Eli Lilly Recent Developments
- 12.8 Jiangsu Nhwa Pharmaceutical Co., Ltd.
- 12.8.1 Jiangsu Nhwa Pharmaceutical Co., Ltd. Company Information
- 12.8.2 Jiangsu Nhwa Pharmaceutical Co., Ltd. Business Overview
- 12.8.3 Jiangsu Nhwa Pharmaceutical Co., Ltd. Revenue in Central Nervous System (CNS) Drug Business (2021-2026)
- 12.8.4 Jiangsu Nhwa Pharmaceutical Co., Ltd. Central Nervous System (CNS) Drug Product Portfolio
- 12.8.5 Jiangsu Nhwa Pharmaceutical Co., Ltd. Recent Developments
- 12.9 Pfizer Inc
- 12.9.1 Pfizer Inc Company Information
- 12.9.2 Pfizer Inc Business Overview
- 12.9.3 Pfizer Inc Revenue in Central Nervous System (CNS) Drug Business (2021-2026)
- 12.9.4 Pfizer Inc Central Nervous System (CNS) Drug Product Portfolio
- 12.9.5 Pfizer Inc Recent Developments
- 12.10 GSK
- 12.10.1 GSK Company Information
- 12.10.2 GSK Business Overview
- 12.10.3 GSK Revenue in Central Nervous System (CNS) Drug Business (2021-2026)
- 12.10.4 GSK Central Nervous System (CNS) Drug Product Portfolio
- 12.10.5 GSK Recent Developments
- 12.11 UCB
- 12.11.1 UCB Company Information
- 12.11.2 UCB Business Overview
- 12.11.3 UCB Revenue in Central Nervous System (CNS) Drug Business (2021-2026)
- 12.11.4 UCB Central Nervous System (CNS) Drug Product Portfolio
- 12.11.5 UCB Recent Developments
- 12.12 Otsuka Pharmaceutical Co., Ltd
- 12.12.1 Otsuka Pharmaceutical Co., Ltd Company Information
- 12.12.2 Otsuka Pharmaceutical Co., Ltd Business Overview
- 12.12.3 Otsuka Pharmaceutical Co., Ltd Revenue in Central Nervous System (CNS) Drug Business (2021-2026)
- 12.12.4 Otsuka Pharmaceutical Co., Ltd Central Nervous System (CNS) Drug Product Portfolio
- 12.12.5 Otsuka Pharmaceutical Co., Ltd Recent Developments
- 12.13 Boehringer Ingelheim
- 12.13.1 Boehringer Ingelheim Company Information
- 12.13.2 Boehringer Ingelheim Business Overview
- 12.13.3 Boehringer Ingelheim Revenue in Central Nervous System (CNS) Drug Business (2021-2026)
- 12.13.4 Boehringer Ingelheim Central Nervous System (CNS) Drug Product Portfolio
- 12.13.5 Boehringer Ingelheim Recent Developments
- 12.14 Biogen Inc
- 12.14.1 Biogen Inc Company Information
- 12.14.2 Biogen Inc Business Overview
- 12.14.3 Biogen Inc Revenue in Central Nervous System (CNS) Drug Business (2021-2026)
- 12.14.4 Biogen Inc Central Nervous System (CNS) Drug Product Portfolio
- 12.14.5 Biogen Inc Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst